

# RESEARCH REPORT



## RESPIRATORY INFECTION DIAGNOSTIC MARKETS

BY TECHNOLOGY, PLEX, PLACE, PRODUCT AND BY REGION WITH  
EXECUTIVE AND CONSULTANT GUIDES 2023-2027





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports, and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

HOWE SOUND RESEARCH

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

|       |                                                                |    |
|-------|----------------------------------------------------------------|----|
| 1     | Market Guides .....                                            | 24 |
| 1.1   | Situation Analysis .....                                       | 25 |
| 1.2   | Guide for Executives and Business Development Staff .....      | 27 |
| 1.3   | Guide for Management Consultants and Investment Advisors ..... | 28 |
| 2     | Introduction and Market Definition .....                       | 29 |
| 2.1   | What are Respiratory Infections?.....                          | 30 |
| 2.2   | The Role of Diagnosis & Treatment.....                         | 34 |
| 2.3   | Market Definition .....                                        | 35 |
| 2.3.1 | Revenue Market Size .....                                      | 35 |
| 2.4   | Methodology .....                                              | 37 |
| 2.4.1 | Methodology .....                                              | 37 |
| 2.4.2 | Sources .....                                                  | 37 |
| 2.4.3 | Authors.....                                                   | 38 |
| 2.5   | Perspective: Healthcare and the IVD Industry.....              | 39 |
| 2.5.1 | Global Healthcare Spending .....                               | 39 |
| 2.5.2 | Spending on Diagnostics .....                                  | 41 |
| 2.5.3 | Important Role of Insurance for Diagnostics.....               | 42 |
| 3     | Market Overview .....                                          | 43 |
| 3.1   | Players in a Dynamic Market .....                              | 44 |

|         |                                               |    |
|---------|-----------------------------------------------|----|
| 3.1.1   | Academic Research Lab.....                    | 46 |
| 3.1.2   | Diagnostic Test Developer.....                | 46 |
| 3.1.3   | Instrumentation Supplier.....                 | 46 |
| 3.1.4   | Chemical/Reagent Supplier.....                | 47 |
| 3.1.5   | Pathology Supplier.....                       | 47 |
| 3.1.6   | Independent Clinical Laboratory.....          | 47 |
| 3.1.7   | Public National/regional Laboratory.....      | 48 |
| 3.1.8   | Hospital Laboratory.....                      | 48 |
| 3.1.9   | Physicians Office Lab (POLs).....             | 49 |
| 3.1.10  | Audit Body.....                               | 50 |
| 3.1.11  | Certification Body.....                       | 50 |
| 3.2     | Respiratory Infections.....                   | 52 |
| 3.2.1   | Upper vs. Lower - Marketing Implications..... | 52 |
| 3.2.2   | Understanding the Role of Pneumonia.....      | 54 |
| 3.2.3   | Bacterial Infections.....                     | 56 |
| 3.2.3.1 | Streptococcal Infections.....                 | 56 |
| 3.2.3.2 | Acute Otitis Media.....                       | 56 |
| 3.2.3.3 | Bacterial Rhinosinusitis.....                 | 57 |
| 3.2.3.4 | Diphtheria.....                               | 57 |
| 3.2.3.5 | Pneumococcal Pneumonia.....                   | 58 |
| 3.2.3.6 | Haemophilus Pneumonia.....                    | 59 |
| 3.2.3.7 | Mycoplasma Pneumonia (Walking Pneumonia)..... | 60 |

|          |                                             |    |
|----------|---------------------------------------------|----|
| 3.2.3.8  | Chlamydial Pneumonias and Psittacosis ..... | 60 |
| 3.2.3.9  | Health Care-Associated Pneumonia .....      | 61 |
| 3.2.3.10 | Pseudomonas Pneumonia.....                  | 62 |
| 3.2.3.11 | Legionnaires Disease .....                  | 65 |
| 3.2.4    | Tuberculosis – A Special Case .....         | 68 |
| 3.2.5    | Viral Infections.....                       | 72 |
| 3.2.5.1  | The Common Cold.....                        | 72 |
| 3.2.5.2  | Influenza .....                             | 73 |
| 3.2.5.3  | Viral Pneumonia .....                       | 79 |
| 3.2.5.4  | SARS and MERS .....                         | 80 |
| 3.2.5.5  | Measles (Rubeola).....                      | 81 |
| 3.2.5.6  | Rubella (German Measles).....               | 82 |
| 3.2.5.7  | Chickenpox and Shingles .....               | 83 |
| 3.2.6    | Fungal and Other Pathogens.....             | 87 |
| 3.2.6.1  | Histoplasmosis .....                        | 87 |
| 3.2.6.2  | Coccidioidomycosis.....                     | 88 |
| 3.2.6.3  | Blastomycosis .....                         | 89 |
| 3.2.6.4  | Mucormycosis .....                          | 90 |
| 3.2.6.5  | Aspergillosis .....                         | 91 |
| 3.2.6.6  | Pneumocystis Pneumonia .....                | 92 |
| 3.2.6.7  | Cryptococcosis.....                         | 92 |
| 3.3      | Diagnostics – A Changing Role .....         | 95 |

|       |                                                            |     |
|-------|------------------------------------------------------------|-----|
| 3.3.1 | Historical Practice .....                                  | 95  |
| 3.3.2 | Current Diagnostics .....                                  | 96  |
| 3.3.3 | The Multiplex Vector.....                                  | 98  |
| 3.3.4 | Future Diagnostics – The Question of When and Where .....  | 99  |
| 3.3.5 | Respiratory Infection Diagnostics – The Destination.....   | 99  |
| 3.3.6 | Diagnostics as Defensive Weapons.....                      | 100 |
| 3.4   | COVID-19 .....                                             | 101 |
| 3.4.1 | Signs and symptoms.....                                    | 103 |
| 3.4.2 | Transmission .....                                         | 105 |
| 3.4.3 | Diagnosis.....                                             | 106 |
| 3.4.4 | Prevention .....                                           | 108 |
| 3.4.5 | Management.....                                            | 109 |
| 3.4.6 | Prognosis.....                                             | 111 |
| 3.5   | Pandemic Diagnostics.....                                  | 112 |
| 3.5.1 | Risk Management – Spark and Spread.....                    | 113 |
| 3.5.2 | Dx Technology – Nucleic Acid Based.....                    | 114 |
| 3.5.3 | Dx Technology - Immunoassay & Serology.....                | 115 |
| 3.5.4 | Time to Market and Preparedness Issues .....               | 116 |
| 3.5.5 | Unrecognized Role of Multiplex in Pandemic Mangement ..... | 117 |
| 4     | Market Trends.....                                         | 119 |
| 4.1   | Factors Driving Growth .....                               | 120 |
| 4.1.1 | Syndromic Multiplexing .....                               | 120 |

|       |                                                                    |     |
|-------|--------------------------------------------------------------------|-----|
| 4.1.2 | T.A.T. ....                                                        | 121 |
| 4.1.3 | Antimicrobial Resistance Movement.....                             | 121 |
| 4.1.4 | Pandemic Mitigation.....                                           | 121 |
| 4.1.5 | An Aging at Risk Population .....                                  | 121 |
| 4.2   | Factors Limiting Growth .....                                      | 123 |
| 4.2.1 | The Cost Curve.....                                                | 123 |
| 4.2.2 | Regulation and coverage .....                                      | 124 |
| 4.2.3 | Laissez Faire .....                                                | 124 |
| 4.3   | Instrumentation and Automation.....                                | 125 |
| 4.3.1 | The Shrinking Multiplexing Machine.....                            | 125 |
| 4.3.2 | Bioinformatics Networking and Anonymous Reporting.....             | 125 |
| 4.4   | Diagnostic Technology Development.....                             | 127 |
| 4.4.1 | The Key Role of Time to Result .....                               | 128 |
| 4.4.2 | Single Cell Genomics Changes the Picture .....                     | 128 |
| 4.4.3 | Pharmacogenomics Blurs Diagnosis and Treatment .....               | 129 |
| 4.4.4 | Pathogen Identification – A Projected Timetable of the Future..... | 130 |
| 5     | Respiratory Infection Diagnostics Recent Developments .....        | 131 |
| 5.1   | Recent Developments – Importance and How to Use This Section ..... | 132 |
| 5.1.1 | Importance of These Developments.....                              | 132 |
| 5.1.2 | How to Use This Section.....                                       | 132 |
| 5.2   | New bioMérieux Respiratory Diagnostic System.....                  | 132 |
| 5.3   | Visby Medical Nabs FDA EUA for POC Respiratory Panel Test .....    | 134 |



|      |                                                                              |     |
|------|------------------------------------------------------------------------------|-----|
| 5.4  | SENZO SECURES FUNDING FOR PCR-ACCURATE LATERAL FLOW TEST .....               | 134 |
| 5.5  | Takara Bio USA, BioExcel Diagnostics Partner for Dx Panels.....              | 135 |
| 5.6  | ProtonDx's Dragonfly Dx System successfully deployed .....                   | 136 |
| 5.7  | Genomtec Gets CE-IVD Mark for POC Respiratory Disease Test .....             | 138 |
| 5.8  | FDA Issues First EUA for Non-Prescription COVID-19/Flu/RSV Test .....        | 138 |
| 5.9  | "Diagnostics for the Real World" Plans Third-Generation POC Platform .....   | 139 |
| 5.10 | Cue Health Targets DTC Market .....                                          | 143 |
| 5.11 | Investors Skeptical of Ortho Clinical Diagnostics Acquisition by Quidel..... | 148 |
| 5.12 | Sense Biodetection to Debut Instrument-Free POC MDx.....                     | 151 |
| 5.13 | LGC Develops 'Ultra-High-Throughput' COVID Workflow .....                    | 156 |
| 5.14 | Cue Health Files for IPO for up to \$100M .....                              | 160 |
| 5.15 | QuantuMDx Developing Multiplex System, Syndromic Panels .....                | 161 |
| 5.16 | Bio-Rad Laboratories Gets CE Mark for Respiratory RT-PCR Assay Kit.....      | 168 |
| 5.17 | BforCure Preparing Multiple Panels for PoC qPCR Platform .....               | 168 |
| 5.18 | Angstrom Bio Raises \$3M in Private Financing.....                           | 173 |
| 5.19 | Test for Them All .....                                                      | 174 |
| 5.20 | Hologic Banking on MDx Acquisitions .....                                    | 175 |
| 5.21 | Pandemic Pushes Handheld qPCR Devices Closer to Commercialization....        | 181 |
| 5.22 | Talis Biomedical 2020 Revenues Rise Sharply .....                            | 190 |
| 5.23 | Luminex to Develop Covid/Flu/RSV Test .....                                  | 191 |
| 5.24 | Becton Dickinson Charts Transition of COVID Diagnostics.....                 | 192 |
| 5.25 | MiRxes Receives Approval for Multiplex Covid/Flu Test .....                  | 196 |

|      |                                                                    |     |
|------|--------------------------------------------------------------------|-----|
| 5.26 | New Silicon-Based Test for Infectious Disease Screening .....      | 196 |
| 5.27 | GenMark to Meet Demand for Respiratory Panel.....                  | 202 |
| 5.28 | Tempus Announces COVID-19 Testing, Data Initiative.....            | 206 |
| 5.29 | Abacus Diagnostica Readying Multiplex Respiratory Test.....        | 210 |
| 5.30 | Qiagen Acquires NeuMoDx Molecular.....                             | 213 |
| 5.31 | Companies Shift to Multiplex Tests for SARS-CoV-2, Influenza ..... | 214 |
| 5.32 | Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel.....    | 223 |
| 5.33 | Cepheid Debuts 10-Color Technology With New Tuberculosis Test..... | 223 |
| 5.34 | BioMérieux's Pneumonia Panel Could Improve Care .....              | 228 |
| 5.35 | Mammoth Biosciences Announces CRISPR-Based C19 Diagnostic.....     | 234 |
| 5.36 | Genetic Signatures Gets CE Mark for C19 Molecular Test.....        | 236 |
| 5.37 | Qiagen Respiratory Panel with C19 Receives CE Mark.....            | 238 |
| 5.38 | Lumos Diagnostics Closes \$15M Series A Funding .....              | 239 |
| 5.39 | Fusion Genomics to Assess NGS Respiratory Tract Assay .....        | 240 |
| 6    | Profiles of Key Players .....                                      | 242 |
| 6.1  | Abacus Diagnostica .....                                           | 243 |
| 6.2  | Abbott Laboratories.....                                           | 244 |
| 6.3  | Accelerate Diagnostics .....                                       | 246 |
| 6.4  | Access Bio.....                                                    | 247 |
| 6.5  | Ador Diagnostics .....                                             | 248 |
| 6.6  | ADT Biotech .....                                                  | 249 |
| 6.7  | Akonni Biosystems .....                                            | 250 |

|      |                                        |     |
|------|----------------------------------------|-----|
| 6.8  | Altona Diagnostics .....               | 252 |
| 6.9  | Alveo Technologies.....                | 253 |
| 6.10 | Anatolia Genetworks .....              | 254 |
| 6.11 | Antelope Dx.....                       | 255 |
| 6.12 | Applied BioCode.....                   | 257 |
| 6.13 | Assurance Scientific Laboratories..... | 259 |
| 6.14 | Aureum Diagnostics .....               | 260 |
| 6.15 | Aus Diagnostics .....                  | 261 |
| 6.16 | Beckman Coulter Diagnostics .....      | 262 |
| 6.17 | Becton, Dickinson and Company .....    | 263 |
| 6.18 | Binx Health .....                      | 265 |
| 6.19 | Biocartis .....                        | 267 |
| 6.20 | BioFire Diagnostics (bioMérieux) ..... | 268 |
| 6.21 | bioMérieux Diagnostics.....            | 270 |
| 6.22 | Bio-Rad Laboratories, Inc. ....        | 273 |
| 6.23 | Bosch Healthcare Solutions GmbH.....   | 276 |
| 6.24 | Celemics .....                         | 277 |
| 6.25 | Cepheid (Danaher) .....                | 278 |
| 6.26 | Chembio .....                          | 280 |
| 6.27 | Co Diagnostics .....                   | 282 |
| 6.28 | Credo Diagnostics Biomedical .....     | 283 |
| 6.29 | Cue Health.....                        | 284 |

|      |                                  |     |
|------|----------------------------------|-----|
| 6.30 | Curetis N.V. / Curetis GmbH..... | 286 |
| 6.31 | Detect .....                     | 288 |
| 6.32 | Diagenode Diagnostics.....       | 289 |
| 6.33 | Diascopic .....                  | 290 |
| 6.34 | Diasorin S.p.A. ....             | 291 |
| 6.35 | Enzo Biochem .....               | 294 |
| 6.36 | Eurofins Scientific .....        | 296 |
| 6.37 | Fluxergy .....                   | 299 |
| 6.38 | Fulgent Genetics.....            | 300 |
| 6.39 | Fusion Genomics. ....            | 301 |
| 6.40 | Genetic Signatures.....          | 303 |
| 6.41 | GenMark Dx (Roche).....          | 304 |
| 6.42 | Hibergene Diagnostics .....      | 306 |
| 6.43 | Hologic .....                    | 307 |
| 6.44 | Immunexpress.....                | 310 |
| 6.45 | Inflammatix .....                | 311 |
| 6.46 | Invetech .....                   | 312 |
| 6.47 | Janssen Diagnostics .....        | 313 |
| 6.48 | Karius .....                     | 314 |
| 6.49 | Lexagene .....                   | 316 |
| 6.50 | LightDeck Diagnostics .....      | 317 |
| 6.51 | Luminex Corp.....                | 318 |

|      |                                    |     |
|------|------------------------------------|-----|
| 6.52 | Lumos Diagnostics.....             | 320 |
| 6.53 | Mammoth Biosciences .....          | 321 |
| 6.54 | Maxim Biomedical .....             | 322 |
| 6.55 | Meridian Bioscience.....           | 323 |
| 6.56 | Mesa Biotech (Thermo Fisher) ..... | 325 |
| 6.57 | Millipore Sigma .....              | 326 |
| 6.58 | Mindray .....                      | 327 |
| 6.59 | Mobidiag (Hologic).....            | 328 |
| 6.60 | Mologic .....                      | 329 |
| 6.61 | Nanomix .....                      | 330 |
| 6.62 | Operon.....                        | 331 |
| 6.63 | Oxford Nanopore Technologies ..... | 332 |
| 6.64 | Panagene .....                     | 334 |
| 6.65 | Perkin Elmer.....                  | 335 |
| 6.66 | Prenetics.....                     | 337 |
| 6.67 | Primerdesign (Novacyt) .....       | 338 |
| 6.68 | Prominex.....                      | 339 |
| 6.69 | Qiagen .....                       | 341 |
| 6.70 | QuantuMDx .....                    | 343 |
| 6.71 | QuidelOrtho .....                  | 344 |
| 6.72 | Roche Molecular Diagnostics .....  | 346 |
| 6.73 | Seegene.....                       | 348 |

|       |                                                                     |     |
|-------|---------------------------------------------------------------------|-----|
| 6.74  | Siemens Healthineers .....                                          | 350 |
| 6.75  | Sona Nanotech .....                                                 | 353 |
| 6.76  | SpeeDx .....                                                        | 355 |
| 6.77  | T2 Biosystems .....                                                 | 356 |
| 6.78  | Talis Biomedical .....                                              | 358 |
| 6.79  | Thermo Fisher Scientific Inc.....                                   | 359 |
| 6.80  | Veramarx .....                                                      | 362 |
| 6.81  | Veredus Laboratories.....                                           | 363 |
| 6.82  | Visby Medical .....                                                 | 364 |
| 6.84  | XCR Diagnostics .....                                               | 366 |
| 6.85  | Zhejiang Orient Gene Biotech .....                                  | 367 |
| 7     | The Global Market for Respiratory Infection Diagnostics .....       | 369 |
| 7.1   | Global Market by Country .....                                      | 370 |
| 7.1.1 | Table – Global Market by Country.....                               | 370 |
| 7.1.2 | Chart - Global Market by Country.....                               | 371 |
| 7.2   | Global Market by Technology - Overview .....                        | 372 |
| 7.2.1 | Table – Global Market by Technology .....                           | 372 |
| 7.2.2 | Chart – Global Market by Technology – Base/End Year Comparison..... | 373 |
| 7.2.3 | Chart – Global Market by Technology – Base Year.....                | 374 |
| 7.2.4 | Chart – Global Market by Technology – End Year.....                 | 375 |
| 7.2.5 | Chart – Global Market by Technology – Share by Year .....           | 376 |
| 7.2.6 | Chart – Global Market by Technology – Segment Growth.....           | 377 |

|       |                                                                       |     |
|-------|-----------------------------------------------------------------------|-----|
| 7.3   | Global Market by Plex - Overview.....                                 | 378 |
| 7.3.1 | Table – Global Market by Plex.....                                    | 378 |
| 7.3.2 | Chart – Global Market by Plex – Base/End Year Comparison.....         | 379 |
| 7.3.3 | Chart – Global Market by Plex – Base Year .....                       | 380 |
| 7.3.4 | Chart – Global Market by Plex – End Year .....                        | 381 |
| 7.3.5 | Chart – Global Market by Plex – Share by Year .....                   | 382 |
| 7.3.6 | Chart – Global Market by Plex – Segment Growth.....                   | 383 |
| 7.4   | Global Market by Place - Overview.....                                | 384 |
| 7.4.1 | Table – Global Market by Place.....                                   | 384 |
| 7.4.2 | Chart – Global Market by Place – Base/End Year Comparison.....        | 385 |
| 7.4.3 | Chart – Global Market by Place – Base Year .....                      | 386 |
| 7.4.4 | Chart – Global Market by Place – End Year.....                        | 387 |
| 7.4.5 | Chart – Global Market by Place – Share by Year .....                  | 388 |
| 7.4.6 | Chart – Global Market by Place – Segments Growth.....                 | 389 |
| 7.5   | Global Market by Product - Overview.....                              | 390 |
| 7.5.1 | Table – Global Market by Product.....                                 | 390 |
| 7.5.2 | Chart – Global Market by Product – Base/End Year Comparison.....      | 391 |
| 7.5.3 | Chart – Global Market by Product – Base Year .....                    | 392 |
| 7.5.4 | Chart – Global Market by Product – End Year .....                     | 393 |
| 7.5.5 | Chart – Global Market by Product – Share by Year.....                 | 394 |
| 7.5.6 | Chart – Global Market by Product – Segments Growth.....               | 395 |
| 8     | Global Respiratory Infection Diagnostic Markets – By Technology ..... | 396 |

|       |                                                                |     |
|-------|----------------------------------------------------------------|-----|
| 8.1   | Microbiology.....                                              | 397 |
| 8.1.1 | Table Microbiology – by Country .....                          | 397 |
| 8.1.2 | Chart - Microbiology Growth .....                              | 398 |
| 8.2   | PCR .....                                                      | 399 |
| 8.2.1 | Table PCR – by Country .....                                   | 399 |
| 8.2.2 | Chart - PCR Growth.....                                        | 400 |
| 8.3   | NGS.....                                                       | 401 |
| 8.3.1 | Table NGS – by Country .....                                   | 401 |
| 8.3.2 | Chart - NGS Growth .....                                       | 402 |
| 8.4   | Immunoassay/Other .....                                        | 403 |
| 8.4.1 | Table Immunoassay – by Country.....                            | 403 |
| 8.4.2 | Chart – Immunoassay/Other Growth .....                         | 404 |
| 8.5   | C19 Singleplex .....                                           | 405 |
| 8.5.1 | Table C19splex – by Country .....                              | 405 |
| 8.5.2 | Chart – C19splex Growth.....                                   | 406 |
| 9     | Global Respiratory Infection Diagnostic Markets – by Plex..... | 407 |
| 9.1   | C19 Single Plex.....                                           | 408 |
| 9.1.1 | Chart – C19 Single Plex Growth.....                            | 409 |
| 9.2   | Singleplex .....                                               | 410 |
| 9.2.1 | Table Singleplex – by Country .....                            | 410 |
| 9.2.2 | Chart - Singleplex Growth.....                                 | 411 |
| 9.3   | Duplex/Triplex .....                                           | 412 |



|        |                                                                    |     |
|--------|--------------------------------------------------------------------|-----|
| 9.3.1  | Table Duplex/Triplex – by Country .....                            | 412 |
| 9.3.2  | Chart - Duplex/Triplex Growth.....                                 | 413 |
| 9.4    | Multiplex Technology.....                                          | 414 |
| 9.4.1  | Table Multiplex – by Country .....                                 | 414 |
| 9.4.2  | Chart - Multiplex Growth.....                                      | 415 |
| 10     | Global Respiratory Infection Diagnostic Markets – by Place .....   | 416 |
| 10.1   | Hospital Lab .....                                                 | 417 |
| 10.1.1 | Table Hospital Lab – by Country.....                               | 417 |
| 10.1.2 | Chart - Hospital Lab Growth .....                                  | 418 |
| 10.2   | Outpatient Lab.....                                                | 419 |
| 10.2.1 | Table Outpatient Lab – by Country .....                            | 419 |
| 10.2.2 | Chart - Outpatient Lab Growth.....                                 | 420 |
| 10.3   | POC .....                                                          | 421 |
| 10.3.1 | Table POC – by Country.....                                        | 421 |
| 10.3.2 | Chart - POC Growth .....                                           | 422 |
| 10.4   | Other Technology .....                                             | 423 |
| 10.4.1 | Chart - Other Growth .....                                         | 424 |
| 11     | Global Respiratory Infection Diagnostic Markets – by Product ..... | 425 |
| 11.1   | Instruments .....                                                  | 426 |
| 11.1.1 | Table Instruments – by Country.....                                | 426 |
| 11.1.2 | Chart - Instruments Growth .....                                   | 427 |
| 11.2   | Consumables.....                                                   | 428 |

- 11.2.1 Table Consumables – by Country .....428
- 11.2.2 Chart - Consumables Growth..... 429
- 11.3 Software & Service ..... 430
  - 11.3.1 Table Software & Service – by Country .....430
  - 11.3.2 Chart – Software & Service Growth .....431
- 12 Appendices.....432
  - 12.1 United States Medicare System: Clinical Laboratory Fees Schedule ..... 433
  - 12.2 The Most Used IVD Assays.....559
  - 12.3 The Highest Grossing Assays .....565

## Table of Tables

|                                                                  |     |
|------------------------------------------------------------------|-----|
| Table 1 Market Players by Type.....                              | 45  |
| Table 2 Bacterial Causes of Pneumonia .....                      | 55  |
| Table 3 List of Influenza Pandemics .....                        | 77  |
| Table 4 Viral Infections of the Respiratory Tract .....          | 86  |
| Table 5 Fungal Infections of the Respiratory Tract .....         | 94  |
| Table 6 Characteristics of Coronavirus Pandemic Infections ..... | 102 |
| Table 7 COVID-19 Symptoms .....                                  | 104 |
| Table 8 Five Factors Driving Growth .....                        | 120 |
| Table 9 Three Factors Limiting Growth.....                       | 123 |
| Table 10 Key Diagnostic Laboratory Technology Trends.....        | 127 |
| Table 11 Long Term Pathogen Identification Timetable .....       | 130 |
| Table 12 - Global Market by Region.....                          | 370 |
| Table 13 Global Market by Technology.....                        | 372 |
| Table 14 Global Market by Plex .....                             | 378 |
| Table 15 Global Market by Place .....                            | 384 |
| Table 16 Global Market by Product .....                          | 390 |
| Table 17 Microbiology by Country.....                            | 397 |
| Table 18 PCR by Country .....                                    | 399 |
| Table 19 NGS by Country.....                                     | 401 |

|                                             |     |
|---------------------------------------------|-----|
| Table 20 Immunoassay/Other by Country ..... | 403 |
| Table 21 C19splex by Country.....           | 405 |
| Table 22 C19 Single Plex by Country .....   | 408 |
| Table 23 Singleplex by Country.....         | 410 |
| Table 24 Duplex/Triplex by Country .....    | 412 |
| Table 25 Multiplex by Country.....          | 414 |
| Table 26 Hospital Lab by Country .....      | 417 |
| Table 27 Outpatient Lab by Country.....     | 419 |
| Table 28 POC by Country .....               | 421 |
| Table 29 Other by Country .....             | 423 |
| Table 30 Instruments by Country.....        | 426 |
| Table 31 Consumables by Country.....        | 428 |
| Table 32 Software & Service by Country..... | 430 |
| Table 33 Laboratory Fee Schedule.....       | 433 |
| Table 34 The Most Common Assays .....       | 559 |
| Table 35 Largest Revenue Assays .....       | 565 |

## Table of Figures

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| Figure 1 Respiratory Tract Infections .....                     | 30  |
| Figure 2 The LRI Mortality Rate Globally .....                  | 32  |
| Figure 3 Global Pandemic Pathogen Status .....                  | 33  |
| Figure 4 Global Healthcare Spending.....                        | 40  |
| Figure 5 The Lab Test Pie .....                                 | 41  |
| Figure 6 The Road to Diagnostics.....                           | 44  |
| Figure 7 The BioFire Respiratory Panel .....                    | 53  |
| Figure 8 Pneumonia .....                                        | 54  |
| Figure 9 Bacterial Infections of the Respiratory Tract.....     | 67  |
| Figure 10 The Development Cycle of Tuberculosis .....           | 70  |
| Figure 11 A Flu Epidemic in Europe – Historical Pattern .....   | 79  |
| Figure 12 The Single Multiplex Shift .....                      | 98  |
| Figure 13 Percentage of World Population Over 65 .....          | 122 |
| Figure 14 Global Market Share Chart .....                       | 371 |
| Figure 15 Global Market by Technology – Base vs. End Year ..... | 373 |
| Figure 16 Global Market by Technology Base Year.....            | 374 |
| Figure 17 Global Market by Technology End Year .....            | 375 |
| Figure 18 Technology Share by Year .....                        | 376 |
| Figure 19 Technology Segments Growth .....                      | 377 |

|                                                       |     |
|-------------------------------------------------------|-----|
| Figure 20 Plex - Base vs. End Year Segment Shift..... | 379 |
| Figure 21 Plex Market Base Year .....                 | 380 |
| Figure 22 Plex Market End Year.....                   | 381 |
| Figure 23 Plex Share by Year .....                    | 382 |
| Figure 24 Plex Segments Growth.....                   | 383 |
| Figure 25 Place - Base vs. End Year .....             | 385 |
| Figure 26 Place Market Base Year .....                | 386 |
| Figure 27 Place Market End Year.....                  | 387 |
| Figure 28 Place Share by Year .....                   | 388 |
| Figure 29 Place Segments Growth.....                  | 389 |
| Figure 30 Product - Base vs. End Year .....           | 391 |
| Figure 31 Product Market Base Year .....              | 392 |
| Figure 32 Product Market End Year.....                | 393 |
| Figure 33 Product Share by Year.....                  | 394 |
| Figure 34 Product Segments Growth.....                | 395 |
| Figure 35 Microbiology Growth.....                    | 398 |
| Figure 36 PCR Diagnostics Growth.....                 | 400 |
| Figure 37 NGS Growth .....                            | 402 |
| Figure 38 Immunoassay/Other Growth .....              | 404 |
| Figure 39 C19splex Growth .....                       | 406 |
| Figure 40 C19 Single Plex Growth.....                 | 409 |
| Figure 41 Singleplex Growth .....                     | 411 |

Figure 42 Duplex/Triplex Growth .....413

Figure 43 Multiplex Growth .....415

Figure 44 Hospital Lab Growth .....418

Figure 45 Outpatient Lab Growth .....420

Figure 46 POC Growth .....422

Figure 47 Other Growth.....424

Figure 48 Instruments Growth .....427

Figure 49 Consumables Growth.....429

Figure 50 Software & Service Growth .....431